A new drug called apitegromab may help users of obesity medications like Ozempic maintain muscle mass while losing weight. Research indicates that a significant portion of weight loss from these drugs can come from muscle rather than fat, leading to unwanted body changes, including the phenomenon known as ‘Ozempic butt.’ In a trial involving 102 adults, those who received apitegromab alongside their weight-loss medication retained more muscle, suggesting a potential solution to this issue.
The implications of this drug extend beyond aesthetics; preserving muscle is crucial for overall health and strength, particularly as rapid weight loss can lead to long-term health risks. While the findings are promising, experts caution that further studies are needed to confirm the benefits of apitegromab and its potential for broader use.
Currently, apitegromab is only available in clinical trials and is administered via infusion. However, the manufacturer is exploring the possibility of a self-injection option, similar to existing obesity drugs. This could make it more accessible for those looking to manage their weight without sacrificing muscle health.
As obesity treatments become more prevalent, understanding the balance between fat loss and muscle preservation will be essential. Users are advised to combine these medications with healthy eating and strength training to optimise their results and maintain their overall well-being.
Source: BBC News
